1 completed, 1 not yet recruiting, 1 recruiting, 1 withdrawn. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Intervention 1: new trials by email Literature Review of Intervention 1 trials Research Report on Intervention 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oxfendazole in Mild Parenchymal Brain Cysticercosis Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis | Phase 2 / Phase 3 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 544 | 2026-12-01 | 2026-05-01 |
| The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients Intervention 1, Intervention 2, Control - Delirium | Phase 2 / Phase 3 | Recruiting | Sultan Qaboos University | 240 | 2024-09-30 | 2025-01-14 |
| A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Oryn Therapeutics, LLC | 2021-04-01 | 2021-06-14 | |
| Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients single dose of L-AmB, 2 doses of L-AmB, 2 weeks of L-AmB - Histoplasmosis, AIDS | Phase 2 | Completed | Alessandro Pasqualotto | 118 | 2020-02-14 | 2025-03-14 |
Acquired Immunodeficiency Syndrome (1) · COVID-19 (1) · Cysticercosis (1) · Delirium (1) · Histoplasmosis (1) · Neurocysticercosis (1)
Alessandro Pasqualotto (1) · Oryn Therapeutics, LLC (1) · Sultan Qaboos University (1) · Universidad Peruana Cayetano Heredia (1)
Brazil (1) · Oman (1) · United States (1)
Alpesh Amin, MD (1) · Daiane Dalla Lana, PhD (1) · Hector H Garcia, MD, PhD (1)